- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01320813
Trial Comparing Complication Rates Associated With Robot-assisted Thyroidectomy to External Thyroidectomy
March 24, 2015 updated by: Centre Hospitalier Universitaire de Nīmes
Randomized Trial Comparing Complication Rates Associated With Robot-assisted Thyroidectomy to External Thyroidectomy
The main objective is to compare 12 month complication rates between a new surgical method for thyroidectomy (robot-assisted endoscopic thyroidectomy via a sub-clavical approach) and open thyroidectomy.
Study Overview
Status
Terminated
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
5
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Gard
-
Nîmes Cedex 09, Gard, France, 30029
- CHU de Nimes - Hopital Universitaire Caremeau
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
16 years to 83 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- The patient must have given his/her informed and signed consent
- The patient must be insured or beneficiary of a health insurance plan
- The patient is available for 12 months of follow-up
- The patient is a candidate for total thyroidectomy because of a nodular pathology, a diffuse goiter, thyroiditis, or Basedow's disease
- Patient has calcitoninemia < 9 ng/pl
- Patient has normal calcemia
- Patient has PTH level between 5 ng/l and 75 ng/l
- The subject has a normal laryngeal mobility
Exclusion Criteria:
- The patient is participating in another study
- The patient is in an exclusion period determined by a previous study
- The patient is under judicial protection, under tutorship or curatorship
- The patient refuses to sign the consent
- It is impossible to correctly inform the patient
- The patient is pregnant
- The patient is breastfeeding
- The patient is not available for 12 months of follow-up
- Subject has a preoperative diagnosis of cancer on fine needle aspiration biopsy of the thyroid or cervical lymph node
- Lymph node metastasis strongly suspected clinically and/or sonographically
- The subject has an extension of substernal thyroid (diving goiter)
- Family history of medullary thyroid cancer
- The subject has a history of neck surgery
- Contraindication for general anesthesia
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Robot arm
Patients in this arm will have a thyroidectomy performed using a robot-assisted endoscopic technique.
|
Patients will have a thyroidectomy via a robot-assisted (da Vinci robot) endoscopic (subclavical entry)surgical technique.
|
Active Comparator: Open surgery
Patients in this arm will have a thyroidectomy using an open surgical technique.
|
Patients will have a conventional (non-endoscopic) thyroidectomy using an open surgical technique
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Presence/absence of complications (composite score)
Time Frame: 12 months
|
The per or post-operative occurrence of at least one of the following: postoperative hemorrhage requiring reintervention; cervical infection requiring antibiotics and/or surgical intervention; transient or persistent laryngeal paralysis; transient or persistent hypoparathyroidy (calcemia < 1.9 µmol/l).
Transiient means < than and persistent means >= 12 months.
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incision size (mm)
Time Frame: 12 months
|
Length of incision in the open group, and sum of incision lengths in the robot group.
|
12 months
|
Patient satisfaction score
Time Frame: 12 months
|
Patient satisfaction as regards the incision scar measured using a visual analog scale from 0.0 to 10.0.
|
12 months
|
Presence/absence of conversion to open technique
Time Frame: 1 day
|
For patients in the robot arm: presence/absence of conversion to open technique.
|
1 day
|
Operating room prep time (min)
Time Frame: 1 day
|
Time in minutes necessary to prep the operating room
|
1 day
|
Presence/absence of per-operative complications
Time Frame: 1 day
|
Presence/absence of per-operative complications
|
1 day
|
Hospital stay (d)
Time Frame: 7 to 15 days post-op
|
Length of hospitalization in days required after thyroidectomy
|
7 to 15 days post-op
|
Change in thyroglobulinemia (ng/l)
Time Frame: 12 months
|
Thyroglobulinemia at 12 months - Thryoglobulinemia as baseline
|
12 months
|
Change in calcemia (mg/l)
Time Frame: Day 1
|
Calcemia on Day 1 - Calcemia at inclusion
|
Day 1
|
Change in calcemia (mg/l)
Time Frame: Day 7 to 15
|
Calcemia at the control visit (days 7 to 15) - Calcemia at inclusion
|
Day 7 to 15
|
Change in calcemia (mg/l)
Time Frame: 12 months
|
Calcemia at 12 months - Calcemia at inclusion
|
12 months
|
Change in phosphoremia (mg/l)
Time Frame: Day 1
|
Phosphoremia at 1 day postop - Phosphoremia at inclusion
|
Day 1
|
Change in phosphoremia (mg/l)
Time Frame: Days 7 to 15
|
Phosphoremia at control visit (days 7 to 15) - Phosphoremia at inclusion
|
Days 7 to 15
|
Change in phosphoremia (mg/l)
Time Frame: 12 months
|
Phosphoremia at 12 months - Phosphoremia at inclusion
|
12 months
|
Change in parathormonemia (ng/l)
Time Frame: Day 1
|
Parathormonemia on Day 1 post-op - parathormonemia at inclusion
|
Day 1
|
Change in parathormonemia (ng/l)
Time Frame: Days 7 to 15
|
Parathormonemia at control visit (days 7 to 15) - parathormonemia at inclusion
|
Days 7 to 15
|
Change in parathormonemia (ng/l)
Time Frame: 12 months
|
Parathormonemia at 12 months - parathormonemia at inclusion
|
12 months
|
Visual Analog Pain Score
Time Frame: Day 1
|
Visual Analog Scale for pain (0.0 to 10.0)
|
Day 1
|
Visual Analog Pain Score
Time Frame: Days 7 to 15
|
Visual Analog Scale for pain (0.0 to 10.0)
|
Days 7 to 15
|
Visual Analog Pain Score
Time Frame: 12 months
|
Visual Analog Scale for pain (0.0 to 10.0)
|
12 months
|
Direct medical costs (€)
Time Frame: 12 months
|
12 months
|
|
Indirect medical costs (€)
Time Frame: 12 months
|
12 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 1, 2011
Primary Completion (Actual)
September 1, 2013
Study Completion (Actual)
September 1, 2013
Study Registration Dates
First Submitted
March 22, 2011
First Submitted That Met QC Criteria
March 22, 2011
First Posted (Estimate)
March 23, 2011
Study Record Updates
Last Update Posted (Estimate)
March 25, 2015
Last Update Submitted That Met QC Criteria
March 24, 2015
Last Verified
March 1, 2015
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- PHRC-I/2010/BL-01
- 2011-A00049-32 (Other Identifier: RCB number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Graves Disease
-
Seoul National University Bundang HospitalActive, not recruitingGraves' Disease in Remission (Disorder)Korea, Republic of
-
The University of Hong KongCompletedRrelapsed Graves' DiseaseHong Kong
-
Fondazione IRCCS Ca' Granda, Ospedale Maggiore...Universität Duisburg-Essen; Cultech Ltd, Port Talbot, UK; School of Medicine... and other collaboratorsUnknown
-
Odense University HospitalCompletedThyroid Associated Ophthalmopathy | Graves´ DiseaseDenmark
-
Assiut UniversityRecruitingRadioactive Iodine-Induced Hypothyroidism in Graves Disease PatientsEgypt
-
Assistance Publique Hopitaux De MarseilleCompleted
-
Mikael LantzCompleted
-
Medical University of ViennaUnknownGraves Ophthalmopathy | Graves Disease | Graves' Ophthalmopathy WorsenedAustria
-
University of Sao PauloCompletedGraves' Ophthalmopathy | Graves' DiseaseBrazil
-
Assiut UniversityNot yet recruitingDoppler Ultrasound in Follow up of Graves' Patients
Clinical Trials on Robot-assisted thyroidectomy
-
Aristotle University Of ThessalonikiAHEPA University HospitalCompleted
-
Institut Paoli-CalmettesNot yet recruiting
-
Cliniques universitaires Saint-Luc- Université...Completed
-
Centre Hospitalier Universitaire de NīmesCompleted
-
City of Hope Medical CenterNational Cancer Institute (NCI)SuspendedDisease or DisorderUnited States
-
National University Hospital, SingaporeNational University, Singapore; Agency for Science, Technology and ResearchCompleted
-
Yingxue HaoUnknown
-
RenJi HospitalUnknown
-
The Affiliated Nanjing Drum Tower Hospital of Nanjing...Active, not recruiting
-
Universita di VeronaCompletedMultiple Sclerosis | RehabilitationItaly